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Introduction
Currently, most of the human beings in the world suffer from
different kinds of diseases caused by DNA and RNA viruses.
These diseases are mostly diagnosed but difficult to cure.
Vaccination is a reliable tool to fight viral diseases, but it is
only available against few viruses. The difficulties associated
with national or worldwide vaccination programs make
antiviral chemotherapy an even more practical approach in
thefight against epidemic viral infections. Nucleoside analogs
are synthetic compounds that are structurally similar to
natural nucleosides and can serve as building blocks of DNA
and RNA. They can act as competitive inhibitors of viral and
cellular DNA and RNA polymerases or alternatively can be
incorporated into growing DNA and RNA strands causing
chain termination [1].
a-Aminophosphonates are defined as structural analogs of
natural amino acids. They are considered as an important class
of compounds with diverse and interesting biological activi-
ties. Some of the aminophosphonates were described as
anticancer agents [2], enzyme inhibitors [3], peptide mimetics
[4], antibiotics and pharmacological agents [5]. They have also
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been reported to be interesting carriers for the transport of
hydrophilic molecules across bilayer lipid membranes [6].
The a-aminophosphonate derivatives are often synthesized
via the Kabachnik–Fields reaction by coupling of a carbonyl
compound, an amine, and a hydroxyphosphoryl compound
using various catalysts [7–9].
1,2,3-Triazoles were prepared by Huisgen in the 1960s [10]
using the 1,3-dipolar cycloaddition reaction with acetylenes.
After approximately four decades, this reaction has acquired
considerable attention owing to the introduction of copper(I)
as catalyst by Medal and then by Sharpless [11–13]. The
copper-catalyzed cycloaddition of azides and alkynes (CuAAC)
also known as “click chemistry” offers a simple access to the
1,4-isomer in very short reaction times.
Further, nucleosides containing 1,2,3-triazole ring have
been of special interest in drug development research. Some
synthetic triazoles have displayed interesting biological
activities and several analogs have been tested against
hepatitis C and HIV-1 viruses [14–18]. Moreover, nucleoside
and acyclonucleoside analogs containing 1,2,3-triazole and
phosphonate structures have been described as potent
antiviral agents [19–21].
Herein, we describe the synthesis of novel hybrid molecules
containing triazolyl-nucleoside linkedtoa-aminophosphonates
by a phenyl ring. The choice of these structures is based
on the combination of both pharmacophore parts, the
phenyl-triazolyl-riboside and the a-aminophosphonates,
which are known to have significant pharmacological
properties. Our synthesis strategy is based on the use of
two reactions: Kabachnick–Fields reaction and 1,3-dipolar
cycloaddition. The compounds obtained were tested against
selected DNA and RNA viruses.
Results and discussion
Chemistry
The synthesis of the desired compounds (4a–j and 5a–j) is
depicted in Scheme 1. Initially, the a-aminophosphonate
compounds were prepared in good yields via the Kabachnik–
Fields reaction. The 4-[(trimethylsilyl)ethynyl]benzaldehyde 1
was reacted with diethylphosphite and corresponding amine
in acetonitrile using molecular iodine as catalyst [22–24]. The
latter is low-priced, readily available, non-metallic, and non-
toxic. The mixture was stirred at room temperature for 1h to
get compounds 2a–j. The next step is deprotection of the
trimethylsilyl group. For this purpose, tetrabutylammonium
fluoride (TBAF) in tetrahydrofurane (THF)was used to give the
terminal alkyne [25]. The structures of 2e, 2f, 3d, and 3g
were confirmed by X-ray diffraction (Fig. 1). According to the
crystal data, the structures are similar for these compounds.
The P–C bond has a staggered conformation, with the two
six-membered groups with respect to the P––O double bond.
The two benzene rings are almost perpendicular in all four
compounds. In each crystal structure (2e, 3d, and 3g), the
molecules are arranged as centrosymmetric or pseudocen-
trosymmetric dimers related by two N–H  O––P hydrogen
bonds. On the other hand, in the crystal structure of 2f,
the hydrogen bond N–H  O––P is not found, and the
molecules are arranged as centrosymmetric dimers linked
by Cmethyl–H  O––P hydrogen bonds [26].
Next, the 1,2,3-triazolyl-nucleosides were prepared using
the 1,3-dipolar cycloaddition reaction. For this, the terminal
alkynes 3a–j and b-azido-ribose [27] were coupled using
the Cu alkyne-azide cycloaddition in basic medium (triethyl-
amine) and the reaction was carried out under microwave
Scheme 1. Reagents and conditions: (i) R-NH2 (1.2 equiv.), H(O)P(OEt)2 (1.2 equiv.), I2 (0.2 equiv.), MeCN, r.t., 1 h; (ii) TBAF (1 equiv.),
THF, r.t., 30min; (iii) azido-ribose (2.5 equiv.), CuI (0.1 equiv.), Et3N (1.1 equiv.), MWI, 5min; (iv) MeONa (1 equiv.), MeOH, r.t., 30min.
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irradiation [28]. Microwave heating has been shown to
increase reaction yields and to speed up reaction time [29],
b-azido-ribose is slightly unstable under micro-wave con-
ditions and was used in excess. The configuration at the
anomeric carbon C10 is retained as it is present in the
b-azido-ribose. The hydroxyl functions were protected by
benzoyl groups prior to the CuAAC reaction in order to
increase the solubility of the compounds. The structures
of all compounds were confirmed on the basis of 1H,
13C NMR spectra as well as by high-resolution mass
spectrometry. In the 1H NMR spectra of the intermediates,
the triazole proton appears as a singlet in the aromatic
region while the anomeric proton appears as a multiplet
around 6 ppm.
The last step involves the removal of the benzoyl protecting
groups from O20, O30, and O50 positions of D-ribose 4a–j using
sodium methoxide (NaOMe) in methanol [30] to afford the
desired 1,2,3-triazole nucleosides 5a–j (Table 1).
Figure 1. X-ray crystallographic structures of compounds 2e, 2f, 3d, and 3g. Displacement ellipsoids are drawn at the 50%probability
level.
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Biological testing
The antiviral activities of the synthesized compounds (4a–j,
5a–j)were tested against different viruses: HIV-1 and HIV-2 in
MT4 cell cultures; herpes simplex virus-1 (HSV-1) (Kos strain),
herpes simplex virus-2 (HSV-2) (G strain), HSV-1 thymidine
kinase deficient, acyclovir-resistant (TK Kos, ACVr), vaccinia
virus, vesicular stomatitis virus (VSV), adenovirus-2, varicella-
zoster virus (VZV) (Oka strain and TK 07/1 strain), human
cytomegalovirus (HCMV) (AD-169 and Davis strain) in human
embryonic lung (HEL) cells; VSV, Coxsackie virus B4, and
respiratory syncytial virus (RSV) in HeLa cells; parainfluenza-3
virus, reovirus-1, Sindbis virus, Coxsackie virus B4, and Punta
Toro virus in Vero cells; feline corona virus (FIPV) and feline
herpes virus in Crandell-Rees Feline Kidney (CRFK) cells,
Table 1. Results of protected (4a–j) and deprotected (5a–j) triazolo nucleoside phosphonates.
Entry R Compounda) Yieldb) (%) Compounda) Yieldc) (%)
1 4a 95 5a 98
2 4b 90 5b 99
3 4c 92 5c 98
4 4d 94 5d 99
5 4e 75 5e 95
6 4f 89 5f 98
7 4g 90 5g 98
8 4h 78 5h 95
9 4i 84 5i 96
10 4j 80 5j 97
a)All products were characterized by 1H NMR, 13C NMR, and mass spectrometry.
b)Yields of isolated products for the CuAAC reaction.
c)Yields of isolated products for the protection reaction.
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influenza A H1N1 subtype, influenza A H3N2 subtype, and
influenza B virus in MDCK (Madin–Darby canine kidney) cells.
The following reference compounds were included: tenofovir
(PMPA), AMD3100, ganciclovir, cidofovir, acyclovir, brivudin,
the lectins Hippeastrum hybrid agglutinin (HHA) and
Urtica dioica agglutinin (UDA), dextran sulfate (molecular
weight 10000, DS-10000), ribavirin, oseltamivir carboxylate,
amantadine and rimantadine, zalcitabine and alovudine.
The antiviral activity was expressed as the EC50: the compound
concentration required to reduce virus-induced cytopatho-
genicity or viral plaque formation by 50%. The cytotoxicity
of the tested compounds toward the uninfected host
cells was defined as the minimum cytotoxic concentration
(MCC) that causes a microscopically detectable alteration of
normal cell morphology. The 50% cytotoxic concentration
(CC50), causing a 50%decrease in cell viability was determined
using a colorimetric 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay
system.
The tested compounds (4a–j, 5a–j) displayed no antiviral
activity against the different viruses tested except for
compounds 4b and 4c that showed a slight inhibition of
respiratory syncytial virus replication (Table 2) and com-
pounds 5c, 5f, and 5g that displayed weak activity against
both TKþ and TK VZV strains (see Supporting Information).
Although compound 4h had some activity against Coxsackie
virus B4 in Vero cell cultures, no activity was seen in HeLa cells
(Tables 2 and 3).
Conclusion
A series of novel 1,2,3-triazolyl ribosides linked to a-amino-
phosphonates (4a–j, 5a–j) were successfully prepared in high
yield via the Kabachnik–Fields reaction and a Cu(I)-catalyzed
alkyne-azide cycloaddition under microwave irradiation.
The synthesized compounds were evaluated against a broad
range of DNA and RNA viruses, some of them showingmodest
activity against respiratory syncytial virus (compounds 4b and
4c) and varicella-zoster virus (compounds 5c, 5f, and 5g).
Experimental
Chemistry
General
Reactions were carried out in a microwave oven model
AVM510/WP/WH. Reactions were monitored by thin layer
chromatography (TLC) on precoated silica gel 60 F254 (Merck,
Darmstadt, Germany); UV light was used for visualization of
the spots. All products were purified by column chromatog-
raphy on silica gel (100–200 mesh; Merck). 1H NMR and
Table 2. Cytotoxicity and antiviral activity of some compounds in HeLa cell cultures.
EC50
b) (mM)
Compound
Minimum cytotoxic
concentrationa) (mM)
Vesicular stomatitis
virus
Coxsackie
virus B4
Respiratory syncytial
virus
4a >50 >50 >50 >50
4b >100 >100 >100 47.5 3.5
4c >100 >100 >100 51.5 9.2
4d >100 >100 >100 72.5 38.9
5i 20 >4 >4 >4
5j 20 >20 >20 >20
DS-10.000 (mg/mL) >100 12 >100 1.3 0.7
Ribavirin >250 22 146 2.9 1.3
a)Required to cause a microscopically detectable alteration of normal cell morphology.
b)Required to reduce virus-induced cytopathogenicity by 50%.
Table 3. Cytotoxicity and antiviral activity of 4h in Vero cell cultures.
Compound
Minimum cytotoxic
concentrationa)
(mM)
EC50
b) (mM)
Parainfluenza-3
virus Reovirus-1
Sindbis
virus
Coxsackie
virus B4
Punta Toro
virus
4h >100 >100 >100 >100 20 >100
DS-10.000 (mg/mL) >100 >100 >100 8.9 >100 8.9
Ribavirin >250 85 >250 >250 >250 112
a)Required to cause a microscopically detectable alteration of normal cell morphology.
b)Required to reduce virus-induced cytopathogenicity by 50%.
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13C NMR spectra were recorded on a Bruker 300 and
75MHz spectrometer, respectively, SiMe4 was used as internal
standard. Chemical shifts are given in ppm and coupling
constants (J) inMHz andmultiplicity is reported as s (singlet), d
(doublet), t (triplet), q (quartet), and m (multiplet). Mass
spectra were produced by ESI/MS and MALDI-TOF-MS.
General procedure for the synthesis of diethyl [(4-(2-
(trimethylsilyl)ethynyl)phenyl)(aryl or alkylamino)methyl]-
phosphonates 2a–j
The compounds 2a–j were synthesized by reaction of
commercial (Sigma–Aldrich) 4-[(trimethylsilyl)ethynyl]benzal-
dehyde 1 (1mmol), diethylphosphite (1.2 equiv.), and
corresponding amine (1.2 equiv.) in acetonitrile (3mL) using
molecular iodine (0.2 equiv.) as catalyst at room temperature,
the reaction mixture was stirred at room temperature for 1 h.
Then, the solvent was removed under reduced pressure. The
resulting residue was purified by column chromatography
using ethyl acetate/hexane as eluent.
Diethyl [(4-(2-(trimethylsilyl)ethynyl)phenyl)-
(phenylamino)methyl]phosphonate 2a
Yield: 95%; Rf: 0.40; Eluent: ethyl acetate/hexane, 7:3 v/v;
1H NMR (300MHz, CDCl3) d (ppm): 0.22 (s, 9H, –CH3), 1.06
(t, 3H, –CH3, J¼ 6.9Hz), 1.20 (t, 3H, –CH3, J¼ 6.9Hz), 3.60–3.68
(m, 1H, –OCH2–), 3.83–3.92 (m, 1H, –OCH2–), 3.97–4.08 (m, 2H,
–OCH2–), 4.62 (d, 1H, CHP, J¼23.7Hz), 5.17 (s, 1H, NH), 6.47 (d,
2H, Ar–H, J¼ 8.1Hz), 6.61 (t, 1H, Ar–H, J¼ 7.2Hz), 7.01 (t, 2H,
Ar–H, J¼ 7.8Hz), 7.33–738 (m, 4H, Ar–H). 13C NMR (75MHz,
CDCl3) d (ppm): 0.06 (Si–CH3), 16.32–16.58 (CH3), 55.20 (CHP),
63.43–63.52 (CH2), 94.74, 104.86 (C–), 114.01, 118.69,
127.84, 129.28, 132.26 (phenyl–CH), 122.81, 136.76, 146.35
(phenyl–C). ESI-MS (MþH),m/z calcd. for C22H30NO3PSi: 415.54,
found: 417.00; HRMS (MþK): calcd. for C22H30NO3PSiK:
454.13642, found: 454.13539.
Diethyl [2-chlorophenylamino][(4-(2-(trimethylsilyl)-
ethynyl)phenyl]methylphosphonate 2b
Yield: 90%; Rf: 0.45; Eluent: ethyl acetate/hexane, 7:3 v/v;
1H NMR (300MHz, CDCl3) d (ppm): 0.10 (s, 9H, –CH3), 1.02 (t, 3H,
–CH3, J¼ 6.9Hz), 1.10 (t, 3H, –CH3, J¼ 6.9Hz), 3.56 (m, 1H,
–OCH2–), 3.81 (m,1H,–OCH2–), 3.95 (m,2H,–OCH2–), 4.54 (d,1H,
CHP, J¼ 24.3Hz), 5.14 (br s, 1H, NH), 6.15 (d, 1H, Ar–H,
J¼ 7.8Hz), 6.63 (t, 1H, Ar–H, J¼7.2Hz), 6.71 (t, 2H, Ar–H,
J¼ 7.5Hz), 6.93–7.19 (m, 4H, Ar–H). 13C NMR (75MHz, CDCl3) d
(ppm): 0.00 (Si–CH3), 16.07–16.50 (CH3), 54.99 (CHP), 63.15–
63.68 (CH2), 94.83, 104.76 (C–), 112.73, 117.82, 118.78, 122.42,
127.06, 127.70, 129.39, 132.46 (phenyl–CH), 122.96 (C–Cl),
120.08, 136.06, 142.29 (phenyl–C). ESI-MS (MþH), m/z calcd.
for C22H29ClNO3PSi: 449.98, found: 451.00; HRMS (MþK): calcd.
for C22H29ClNO3PSiK: 488.09744, found: 488.09631.
Diethyl [2-bromophenylamino][(4-(2-(trimethylsilyl)-
ethynyl)phenyl]methylphosphonate 2c
Yield: 89%; Rf: 0.45; Eluent: ethyl acetate/hexane, 7:3 v/v;
1H NMR (300MHz, CDCl3) d (ppm): 0.10 (s, 9H, –CH3), 0.99 (t,
3H, –CH3, J¼7.2Hz), 1.07 (t, 3H, –CH3, J¼ 7.2Hz), 3.57 (m, 1H,
–OCH2–), 3.76 (m, 1H, –OCH2–), 3.91 (m, 2H, –OCH2–), 4.54 (d,
1H, CHP, J¼24.6Hz), 5.21 (br s, 1H, NH), 6.12 (d, 1H, Ar–H,
J¼ 8.1Hz), 6.63 (t, 1H, Ar–H, J¼7.5Hz), 6.71 (t, 2H, Ar–H,
J¼ 7.5Hz), 7.15–7.29 (m, 4H, Ar–H). 13C NMR (75MHz, CDCl3) d
(ppm): 0.00 (Si–CH3), 16.30–16.52 (CH3), 55.20 (CHP), 63.43–
63.72 (CH2), 94.83, 104.76 (C–), 110.57 (C–Br), 112.77,
119.27, 127.60, 128.36, 132.46–132.52 (phenyl–CH), 122.87,
135.91, 143.07 (phenyl–C). ESI-MS (MþH), m/z calcd. for
C22H29BrNO3PSi: 494.43, found: 496.00; HRMS (MþNa): calcd.
for C22H29BrNO3PSiNa: 516.07299, found: 516.07122.
Diethyl [4-bromophenylamino][(4-(2-(trimethylsilyl)-
ethynyl)phenyl]methylphosphonate 2d
Yield: 92%; Rf: 0.40; Eluent: ethyl acetate/hexane, 7:3 v/v;
1H NMR (300MHz, CDCl3) d (ppm): 0.02 (s, 9H, –CH3), 0.92 (t,
3H, –CH3, J¼6.3Hz), 1.02 (t, 3H, –CH3, J¼ 6.3Hz), 3.49 (m, 1H,
–OCH2–), 3.71 (m, 1H, –OCH2–), 3.88 (m, 2H, –OCH2–), 4.42
(d, 1H, CHP, J¼24.3Hz), 4.65 (br s, 1H, NH), 6.17 (d, 2H, Ar–H,
J¼ 9.0Hz), 6.93 (d, 2H, Ar–H, J¼8.7Hz), 7.12 (d, 2H, Ar–H,
J¼ 8.1Hz), 7.19 (d, 2H, Ar–H, J¼ 8.1Hz). 13C NMR (75MHz,
CDCl3) d (ppm): 0.00 (Si–CH3), 16.28–16.53 (CH3), 55.15 (CHP),
63.44–63.67 (CH2), 94.98, 104.62 (C–), 110.49 (C–Br), 115.58,
127.70, 131.98–132.36 (phenyl–CH), 122.95, 136.02, 145.11
(phenyl–C). ESI-MS (MþH), m/z calcd. for C22H29BrNO3PSi:
494.43, found: 494.90; HRMS (MþNa): calcd. for
C22H29BrNO3PSiNa: 516.07299, found: 516.07251.
Diethyl [4-fluorophenylamino][(4-(2-(trimethylsilyl)-
ethynyl)phenyl]methylphosphonate 2e
Yield: 77%; Rf: 0.36; Eluent: ethyl acetate/hexane, 7:3 v/v;
1H NMR (300MHz, CDCl3) d (ppm): 0.01 (s, 9H, –CH3), 0.91 (t,
3H, –CH3, J¼6.7Hz), 1.07 (t, 3H, –CH3, J¼ 6.7Hz), 3.44 (m, 1H,
–OCH2–), 3.74 (m, 1H, –OCH2–), 3.87 (m, 2H, –OCH2–), 4.44 (d,
1H, CHP, J¼24.3Hz), 5.20 (br s, 1H, NH), 6.25 (d, 2H, Ar–H,
J¼ 6.6Hz), 6.55 (d, 2H, Ar–H, J¼ 6.6Hz), 7.15–7.22 (m, 4H,
Ar–H). 13C NMR (75MHz, CDCl3) d (ppm): 0.00 (Si–CH3), 16.25–
16.51 (CH3), 55.73 (CHP), 63.55–63.64 (CH2), 94.87, 104.70
(C–), 114.95–115.84, 127.82, 132.31 (phenyl–CH), 122.87,
136.32, 142.58 (phenyl–C), 154.84 (C–F). ESI-MS (MþH), m/z
calcd. for C22H29FNO3PSi: 433.53, found: 434.80; HRMS (MþK):
calcd. for C22H29FNO3PSiK: 472.12699, found: 472.12658.
Diethyl [4-chloro-2-methylphenylamino][(4-(2-
(trimethylsilyl)ethynyl)phenyl]methylphosphonate 2f
Yield: 87%; Rf: 0.43; Eluent: ethyl acetate/hexane, 7:3 v/v;
1H NMR (300MHz, CDCl3) d (ppm): 0.01 (s, 9H, –CH3), 0.89 (t,
3H, –CH3, J¼6.9Hz), 1.02 (t, 3H, –CH3, J¼6.9Hz), 1.99 (s, 3H,
Ar–CH3), 3.48 (m, 1H, –OCH2–), 3.72 (m, 1H, –OCH2–), 3.86 (m,
2H, –OCH2–), 4.43 (d, 1H, CHP, J¼ 24.6Hz), 4.54 (s, 1H, NH),
6.00 (d, 1H, Ar–H, J¼8.4Hz), 6.93 (d, 1H, Ar–H, J¼ 8.4Hz), 6.76
(s, 1H, Ar–H), 7.14–7.22 (m, 4H, Ar–H). 13C NMR (75MHz,
CDCl3) d (ppm): 0.00 (Si–CH3), 16.26–16.51, 17.38 (CH3), 55.26
(CHP), 63.40–63.53 (CH2), 94.81, 104.74 (C–), 124.81 (C–Cl),
112.56, 126.58, 127.59, 129.96–132.28 (phenyl–CH), 122.90,
136.27, 142.92 (phenyl–C). ESI-MS (MþH), m/z calcd. for
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C23H31ClNO3PSi: 464.01, found: 465.10; HRMS (MþK): calcd.
for C23H31ClNO3PSiK: 502,11309, found: 502.11199.
Diethyl (4-(2-(trimethylsilyl)ethynyl)phenyl)(2-
naphthalenylamino)methylphosphonate 2g
Yield: 88%; Rf: 0.50; Eluent: ethyl acetate/hexane, 7:3 v/v;
1H NMR (300MHz, CDCl3) d (ppm): 0.26 (s, 9H, –CH3), 1.18 (t,
3H, –CH3, J¼6.9Hz), 1.31 (t, 3H, –CH3, J¼ 6.9Hz), 3.78 (m, 1H,
–OCH2–), 4.01 (m, 1H, –OCH2–), 4.15 (m, 2H, –OCH2–), 4.94 (d,
1H, CHP, J¼ 24.3Hz), 6.10 (br s, 1H, NH), 6.69 (s, 1H, Ar–H), 6.61
(d, 1H, Ar–H, J¼ 7.2Hz), 7.20–7.74 (m, 9H, Ar–H). 13C NMR
(75MHz, CDCl3) d (ppm): 0.00 (Si–CH3), 16.13–16.52 (CH3),
55.09 (CHP), 63.00–63.64 (CH2), 94.77, 104.80 (C–), 106.48,
118.16, 122.80, 126.12, 127.69–132.30 (phenyl–CH), 123.97,
126.85, 134.74, 136.43, 143.99 (phenyl–C). ESI-MS (MþH), m/z
calcd. for C26H32NO3PSi: 465.60, found: 467.20; HRMS (MþNa):
calcd. for C26H32NO3PSiNa: 488.17813, found: 488.17658.
Diethyl (benzylamino)(4-(2-(trimethylsilyl)ethynyl)phenyl)-
methylphosphonate 2h
Yield: 78%; Rf: 0.50; Eluent: ethyl acetate/hexane, 7:3 v/v;
1H NMR (300MHz, CDCl3) d (ppm): 0.70 (s, 9H, –CH3), 0.97 (t,
3H, –CH3, J¼ 6.9Hz), 1.10 (t, 3H, –CH3, J¼ 6.9Hz), 2.27 (br s,
1H, NH), 3.31 (d, 1H, CHP, J¼24.5Hz), 3.64 (m, 2H, –CH2–NH–),
3.78–3.98 (m, 4H, –OCH2–), 7.04–7.13 (m, 5H, Ar–H), 7.20 (d,
2H, Ar–H, J¼8.1Hz), 7.33 (d, 2H, Ar–H, J¼ 8.1Hz). 13C NMR
(75MHz, CDCl3) d (ppm): 0.06 (Si–CH3), 16.25–16.48 (CH3),
51.08 (CH2–N), 58.40 (CHP), 61.75–63.10 (CH2), 94.54, 104.87
(C–), 127.22, 128.33–132.08 (phenyl–CH), 122.65, 136.42–
139.10 (phenyl–C). ESI-MS (MþH),m/z calcd. for C23H32NO3PSi:
429.56, found: 431.00; HRMS (MþH): calcd. for C23H32NO3PSi:
430.19618, found: 430.19647.
Diethyl (dodecylamino)(4-(2-(trimethylsilyl)ethynyl)-
phenyl)methylphosphonate 2i
Yield: 88%; Rf: 0.40; Eluent: ethyl acetate/hexane, 7:3 v/v;
1H NMR (300MHz, CDCl3) d (ppm): 0.07 (s, 9H, –CH3), 0.63 (m,
6H, –OCH2CH3, –CH3), 0.87–1.24 (m, 23H, –CH2–, –OCH2CH3),
2.25 (m, 2H, –CH2–NH–), 3.18 (br s, 1H, NH), 3.68–3.93 (m, 4H,
–OCH2–), 5.26 (d, 1H, CHP, J¼ 23.4Hz), 7.17 (d, 2H, Ar–H,
J¼ 8.2Hz), 7.59 (d, 2H, Ar–H, J¼ 8.2Hz). 13C NMR (75MHz,
CDCl3) d (ppm): 0.00 (Si–CH3), 14.00, 16.25–16.48 (CH3), 22.50,
27.00, 29.11–37.56 (CH2), 59.56 (CHP), 63.09–63.25 (CH2),
94.54, 104.87 (C–), 128.64, 132.05 (phenyl–CH), 123.06,
135.00 (phenyl–C). ESI-MS (MþH),m/z calcd. for C28H50NO3PSi:
507.76, found: 509.40; HRMS (MþH): calcd. for C28H50NO3PSi:
508.33703, found: 508.33659.
Diethyl (octadecylamino)(4-(2-(trimethylsilyl)ethynyl)-
phenyl)methylphosphonate 2j
Yield: 86%; Rf: 0.40; Eluent: ethyl acetate/hexane, 7:3 v/v;
1H NMR (300MHz, CDCl3) d (ppm): 0.25 (t, 9H, –CH3), 0.86 (m,
6H, –OCH2CH3, –CH3), 1.05–1.70 (m, 35H, –CH2–, –OCH2CH3),
2.53 (m, 2H, –CH2–NH–), 3.43 (br s, 1H, NH), 3.78–4.16 (m, 4H,
–OCH2–, CHP), 7.36 (d, 2H, Ar–H, J¼ 8.2Hz), 7.62 (d, 2H, Ar–H,
J¼ 8.2Hz). 13C NMR (75MHz, CDCl3) d (ppm): 0.00 (Si–CH3),
14.19, 16.00–16.50 (CH3), 22.74, 26.88–27.23, 29.51–30.30,
32.06, 29.11–37.56 (CH2), 59.50 (CHP), 63.00–63.50 (CH2),
94.50, 104.00 (C–), 128.50, 132.00 (phenyl–CH), 123.00,
135.00 (phenyl–C). ESI-MS (MþH),m/z calcd. for C34H62NO3PSi:
591.92, found: 593.50; HRMS (MþH): calcd. for C34H62NO3PSi:
592.43093, found: 592.42999.
General procedure for the synthesis of diethyl [(4-(2,3,5-
tri-O-benzoyl-b-D-ribofuranos-1-yl)-1,2,3-triazol-4-yl)(aryl
or alkylamino)(phenyl)methyl]phosphonates 4a–j
The trimethylsilyl ethynyl phenyl a-aminophosphonates 2
(0.7mmol) were reacted with tetrabutylammonium fluoride
(1 equiv.) in tetrahydrofurane (2.5mL). After 30min of stirring
at room temperature, the reaction mixture was purified by
silica gel column chromatography to get ethynyl phenyl a-
aminophosphonates (3a–j).
The terminal alkyne 3 (0.5mmol) and b-azido-ribose (2.5
equiv.) and triethyl amine (1.1 equiv.) were mixed with CuI
(0.1 equiv.). The reaction mixture was homogenized in dry
acetonitrile (1mL) and stirred for 5min. The solvent was
evaporated under vacuum. The reaction mixture was then
irradiated at the power level 400W for 2–5min. The residue
was purified on silica gel using ethyl acetate/hexane as eluent.
Diethyl [(4-(2,3,5-tri-O-benzoyl-b-D-ribofuranos-1-yl)-
1,2,3-triazol-4-yl)phenyl)(phenylamino)methyl]-
phosphonate 4a
Yield: 95%; Rf: 0.45; Eluent: ethyl acetate/hexane, 8:2 v/v;
1H NMR (300MHz, CDCl3) d (ppm): 1.11 (t, 3H, –CH3, J¼ 6.9Hz),
1.26 (t, 3H, –CH3, J¼ 6.9Hz), 3.72 (m, 1H, –OCH2–), 3.95 (m, 1H,
–OCH2–), 4.11 (m, 2H, –OCH2–), 4.60 (m, 1H, H50), 4.77 (d, 1H,
CHP, J¼ 25.2Hz), 4.85–4.91 (m, 1H, H50,H40, H30, NH), 6.16 (m,
1H, H20), 6.30 (m, 1H, H10), 6.53–6.74 (m, 4H, Ar–H), 7.13 (m, 2H,
Ar–H), 7.31–7.68 (m, 12H, Ar–H, CH–triazole), 7.89–8.08 (m,
7H, Ar–H). 13C NMR (75MHz, CDCl3) d (ppm): 15.54, 15.80
(CH3), 54.30 (CHP), 62.64–62.76 (C50, CH2), 70.87 (C20), 74.61
(C30), 80.58 (C40), 89.73 (C10), 113.26, 117.87, 125.30, 127.86,
128.52, 129.13, 133.05 (phenyl–CH, triazole–CH), 135.51,
145.66, 147.22 (phenyl–C, triazole–C), 164.37, 164.48, 165.40
(CO). ESI-MS (MþH), m/z calcd. for C45H43N4O10P: 830.82,
found: 831.40; HRMS (MþK): calcd. for C45H43N4O10PK:
869.23484, found: 869.23435.
Diethyl [(4-(1-(2,3,5-tri-O-benzoyl-b-D-ribofuranos-1-yl)-
1,2,3-triazol-4-yl)phenyl)(2-chlorophenylamino)methyl]-
phosphonate 4b
Yield: 90%; Rf: 0.45; Eluent: ethyl acetate/hexane, 8:2 v/v;
1H NMR (300MHz, CDCl3) d (ppm): 1.12 (t, 3H, –CH3, J¼ 6.9Hz),
1.29 (t, 3H, –CH3, J¼ 6.9Hz), 3.70 (m, 1H, –OCH2–), 3.81 (m, 1H,
–OCH2–), 3.95–4.23 (m, 2H, –OCH2–), 4.61 (m, 1H, H50), 4.77–
4.90 (m, 3H, CHP, H50,H40), 5.45 (m, 1H, H30), 5.70 (br s, 1H, NH),
6.17 (m, 1H, H20), 6.30 (m, 1H, H10), 6.46–6.66 (m, 3H, Ar–H),
6.86–6.98 (m, 2H, Ar–H), 7.15–7.67 (m, 12H, Ar–H,
CH–triazole), 7.88–8.05 (m, 7H, Ar–H). 13C NMR (75MHz,
CDCl3) d (ppm): 16.25, 16.48 (CH3), 54.85 (CHP), 63.15–63.64
(C50, CH2), 71.56 (C20), 75.29 (C30), 81.21 (C40), 90.41 (C10),
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112.76, 117.66, 118.67, 122.33, 126.03, 128.18, 128.64, 129.35,
133.73 (phenyl–CH, triazole–CH), 120.09 (C–Cl), 135.56,
142.19, 147.78 (phenyl–C, triazole–C), 165.36, 165.40, 166.47
(CO). ESI-MS (MþH), m/z calcd. for C45H42ClN4O10P: 865.26,
found: 865.50; HRMS (MþK): calcd. for C45H42ClN4O10PK:
903.19587, found: 903.19617.
Diethyl [(4-(1-(2,3,5-tri-O-benzoyl-b-D-ribofuranos-1-yl)-
1,2,3-triazol-4-yl)phenyl)(2-bromophenylamino)methyl]-
phosphonate 4c
Yield: 92%; Rf: 0.45; Eluent: ethyl acetate/hexane, 8:2 v/v;
1H NMR (300MHz, CDCl3) d (ppm): 1.09–1.25 (t, 6H, –CH3), 3.79
(m, 1H, –OCH2–), 3.92 (m, 1H, –OCH2–), 3.94–3.99 (m, 2H,
–OCH2–), 4.52 (m, 1H, H50), 4.67–4.82 (m, 4H, CHP, NH, H50,H40),
5.45 (m, 1H, H30), 6.04 (m, 1H, H20), 6.19 (m, 1H, H10), 6.33–6.66
(m, 3H, Ar–H), 6.94 (m, 2H, Ar–H), 7.19–7.46 (m, 12H, Ar–H,
CH–triazole), 7.79–8.03 (m, 7H, Ar–H). 13C NMR (75MHz,
CDCl3) d (ppm): 16.27, 16.50 (CH3), 55.08 (CHP), 63.43–63.69
(C50, CH2), 71.55 (C20), 75.24 (C30), 81.27 (C40), 90.41 (C10),
110.59 (C–Br), 112.81, 118.53, 119.16, 126.05, 128.12–129.89,
132.51, 133.50 (phenyl–CH, triazole–CH), 135.52, 143.19–
147.83 (phenyl–C, triazole–C), 165.04–166.08 (CO). ESI-MS
(MþH), m/z calcd. for C45H42BrN4O10P: 909.71, found: 910.70;
HRMS (MþK): calcd. for C45H42BrN4O10PK: 947.14535, found:
947.14589.
Diethyl [(4-(1-(2,3,5-tri-O-benzoyl-b-D-ribofuranos-1-yl)-
1,2,3-triazol-4-yl)phenyl)(4-bromophenylamino)methyl]-
phosphonate 4d
Yield: 94%; Rf: 0.45; Eluent: ethyl acetate/hexane, 8:2 v/v;
1H NMR (300MHz, CDCl3) d (ppm): 1.11 (t, 3H, –CH3, J¼ 6.3Hz),
1.29 (t, 3H, –CH3, J¼ 6.3Hz), 3.69 (m, 1H, –OCH2–), 3.93 (m, 1H,
–OCH2–), 4.12 (m, 2H, –OCH2–), 4.59 (m, 1H, H50), 4.70 (d, 1H,
CHP, J¼24.3Hz), 4.78–4.89 (m, 3H, H50, H40, H30), 5.20 (br s, 1H,
NH), 6.17 (m, 1H, H20), 6.31 (m, 1H, H10), 6.54 (m, 3H, Ar–H), 7.15
(m, 2H, Ar–H), 7.31–7.63 (m, 12H, Ar–H, CH–triazole), 7.85–
8.07 (m, 7H, Ar–H). 13C NMR (75MHz, CDCl3) d (ppm): 16.21,
16.48 (CH3), 54.85 (CHP), 63.38–63.60 (C50, CH2), 71.59 (C20),
75.25 (C30), 81.20 (C40), 90.41 (C10), 110.16 (C–Br), 115.56,
118.82, 126.03, 128.27–129.86, 131.87, 133.71 (phenyl–CH,
triazole–CH), 135.67, 145.32–147.74 (phenyl–C, triazole–C),
165.04–166.06 (CO). ESI-MS (MþH), m/z calcd. for
C45H42BrN4O10P: 909.71, found: 911.30; HRMS (MþNa): calcd.
for C45H42BrN4O10PNa: 931.17141, found: 931.17355.
Diethyl [(4-(1-(2,3,5-tri-O-benzoyl-b-D-ribofuranos-1-yl)-
1,2,3-triazol-4-yl)phenyl)(4-fluorophenylamino)methyl]-
phosphonate 4e
Yield: 75%; Rf: 0.40; Eluent: ethyl acetate/hexane, 8:2 v/v;
1H NMR (300MHz, CDCl3) d (ppm): 1.12 (t, 3H, –CH3, J¼ 6.9Hz),
1.30 (t, 3H, –CH3, J¼ 6.9Hz), 3.72 (m, 1H, –OCH2–), 3.97 (m, 1H,
–OCH2–), 4.13 (m, 2H, –OCH2–), 4.60 (m, 1H, H50), 4.78–4.89 (m,
4H, CHP, H50, H40, H30), 5.15 (br s, 1H, NH), 6.16 (m, 1H, H20), 6.30
(m, 1H, H10), 6.54 (m, 3H, Ar–H), 6.82 (m, 2H, Ar–H), 7.32–7.67
(m, 12H, Ar–H, CH–triazole), 7.91–8.10 (m, 7H, Ar–H). 13C NMR
(75MHz, CDCl3) d (ppm): 16.22–16.48 (CH3), 55.60 (CHP),
63.33–63.51 (C50, CH2), 71.59 (C20), 75.28 (C30), 81.25 (C40),
90.42 (C10), 114.88–115.81, 118.63, 126.03, 128.28–129.88,
133.45, 133.88 (phenyl–CH, triazole–CH), 135.96, 142.46–
147.83 (phenyl–C), 154.76 (triazole–C), 157.89 (C–F), 165.06–
166.08 (CO). ESI-MS (MþH), m/z calcd. for C45H42FN4O10P:
848.81, found:849.10;HRMS(MþK): calcd. forC45H42FN4O10PK:
887.22542, found: 887.22670.
Diethyl [(4-(1-(2,3,5-tri-O-benzoyl-b-D-ribofuranos-1-yl)-
1,2,3-triazol-4-yl)phenyl)(4-chloro-2-methylphenylamino)-
methyl]phosphonate 4f
Yield: 89%; Rf: 0.40; Eluent: ethyl acetate/hexane, 8:2 v/v;
1H NMR (300MHz, CDCl3) d (ppm): 1.13 (t, 3H, –CH3, J¼ 6.9Hz),
1.29 (t, 3H, –CH3, J¼6.9Hz), 2.28 (s, 3H, Ar–CH3), 3.75 (m, 1H,
–OCH2–), 3.98 (m, 1H, –OCH2–), 4.15 (m, 2H, –OCH2–), 4.59 (m,
1H, H50), 4.63–4.90 (m, 4H, CHP, H50, H40, H30), 5.10 (br s, 1H, NH),
6.17 (m, 1H, H20), 6.30 (m, 2H, Ar–H), 6.54 (m, 1H, H10), 6.91 (d,
1H, Ar–H, J¼ 8.4Hz), 7.03 (s, 1H, Ar–H), 7.33–7.65 (m, 12H,
Ar–H, CH–triazole), 7.90–8.05 (m, 7H, Ar–H). 13C NMR (75MHz,
CDCl3) d (ppm): 16.23–16.49, 17.40 (CH3), 55.13 (CHP), 60.35,
63.36–63.46 (C50, CH2), 71.59 (C20), 75.25 (C30), 81.22 (C40),
90.41 (C10), 112.52, 118.72, 126.05, 128.07–129.94, 133.43–
133.87 (phenyl–CH, triazole–CH), 122.80 (C–Cl), 135.79–142.99
(phenyl–C), 147.76 (triazole–C), 165.04–166.06 (CO). ESI-MS
(MþH), m/z calcd. for C46H44ClN4O10P: 879.29, found: 880.00;
HRMS (MþK): calcd. for C46H44ClN4O10PK: 917.21206, found:
917.21196.
Diethyl [(4-(1-(2,3,5-tri-O-benzoyl-b-D-ribofuranos-1-yl)-
1,2,3-triazol-4-yl)phenyl)(2-naphthalenylamino)methyl]-
phosphonate 4g
Yield: 90%; Rf: 0.45; Eluent: ethyl acetate/hexane, 8:2 v/v;
1H NMR (300MHz, CDCl3) d (ppm): 0.98 (t, 3H, –CH3, J¼ 6.9Hz),
1.19 (t, 3H, –CH3, J¼ 6.9Hz), 3.61 (m, 1H, –OCH2–), 3.84 (m, 1H,
–OCH2–), 4.03 (m, 2H, –OCH2–), 4.45 (m, 1H, H50), 4.65–4.88 (m,
3H, CHP, H50, H40), 5.19 (br s, 1H, NH), 6.03 (m, 1H, H30), 6.19 (m,
1H, H20), 6.38 (d, 1H, H10, J¼ 3.3Hz), 6.61 (s, 1H, Ar–H), 6.90–
7.53 (m, 19H, Ar–H, CH–triazole), 7.76–7.89 (m, 7H, Ar–H).
13C NMR (75MHz, CDCl3) d (ppm): 16.33–16.51 (CH3), 54.91
(CHP), 56.91, 63.45–63.59 (C50, CH2), 71.59 (C20), 75.26 (C30),
81.21 (C40), 90.41 (C10), 106.50, 118.20, 118.78, 122.51, 126.34,
127.58–129.88, 133.43–133.86 (phenyl–CH, triazole–CH),
134.78, 136.00, 143.92–144.12 (phenyl–C), 147.84 (triazole–C),
165.03–166.06 (CO). ESI-MS (MþH), m/z calcd. for
C49H45N4O10P: 880.88, found: 882.00; HRMS (MþH): calcd.
for C49H45N4O10P: 919.25049, found: 919.24998.
Diethyl [(4-(1-(2,3,5-tri-O-benzoyl-b-D-ribofuranos-1-yl)-
1,2,3-triazol-4-yl)phenyl)(benzylamino)methyl]-
phosphonate 4h
Yield: 78%; Rf: 0.40; Eluent: ethyl acetate/hexane, 8:2 v/v;
1H NMR (300MHz, CDCl3) d (ppm): 1.08 (t, 3H, –CH3, J¼ 6.9Hz),
1.21 (t, 3H, –CH3, J¼6.9Hz), 3.06 (br s, 1H, NH), 3.48 (d, 1H,
CHP, J¼ 23.4Hz), 3.72 (m, 2H, –CH2–NH–), 3.76–4.02 (m, 4H,
–OCH2–), 4.55 (m, 1H, H50), 4.77–4.82 (m, 2H, H40, H50), 6.06 (m,
1H, H30), 6.21 (m, 1H, H20), 6.46 (m, 1H, H10, J¼3.6Hz), 7.17–
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7.47 (m, 16H, Ar–H, CH–triazole), 7.60 (d, 2H, Ar–H, J¼ 7.8Hz),
7.76–7.89 (m, 7H, Ar–H). 13C NMR (75MHz, CDCl3) d (ppm):
16.32–16.48 (CH3), 51.28 (CHP), 62.92–63.57 (C50, CH2), 71.64
(C20), 75.28 (C30), 81.26 (C40), 90.42 (C10), 118.56, 125.89,
127.18,128.36–129.89,133.47–133.88(phenyl–CH,triazole–CH),
135.50, 139.19 (phenyl–C), 148.01 (triazole–C), 165.07–166.09
(CO). ESI-MS (MþH),m/z calcd. for C46H45N4O10P: 844.84, found:
845.40; HRMS (MþK): calcd. for C46H45N4O10PK: 883.25049,
found: 883.24988.
Diethyl [(4-(1-(2,3,5-tri-O-benzoyl-b-D-ribofuranos-1-yl)-
1,2,3-triazol-4-yl)phenyl)(dodecylamino)methyl]-
phosphonate 4i
Yield: 84%; Rf: 0.50; Eluent: ethyl acetate/hexane, 8:2 v/v;
1H NMR (300MHz, CDCl3) d (ppm): 0.68 (t, 3H, –CH3, J¼ 6.6Hz),
0.97 (t, 3H, –CH3, J¼6.9Hz), 0.99–1.32 (m, 23H, –CH3, –CH2–),
2.31 (m, 2H, –CH2–NH–), 3.01 (br s, 1H, NH), 3.67 (m, 1H,
–OCH2–), 3.73–3.99 (m, 4H, –OCH2–, CHP), 4.42 (m, 1H, H50),
4.77–4.82 (m, 2H, H40, H50), 5.97 (m, 1H, H30), 6.11 (m, 1H, H20),
6.45 (d, 1H, H10, J¼4.0Hz), 7.19–7.44 (m, 13H, Ar–H,
CH–triazole), 7.77–7.89 (m, 7H, Ar–H). 13C NMR (75MHz,
CDCl3) d (ppm): 14.50, 16.32–16.47 (CH3), 22.50, 27.00, 28.72–
33.87, 40.21 (CH2), 55.00 (CHP), 63.00–63.49 (C50, CH2), 71.59
(C20), 75.28 (C30), 81.31 (C40), 90.48 (C10), 119.16, 124.79,
125.71, 126.50, 127.42–133.88 (phenyl–CH, triazole–CH),
135.88–136.76 (phenyl–C), 147.50 (triazole–C), 165.00–
166.00 (CO). ESI-MS (MþH), m/z calcd. for C51H63N4O10P:
923.04, found: 924.00.
Diethyl [(4-(1-(2,3,5-tri-O-benzoyl-b-D-ribofuranos-1-yl)-
1,2,3-triazol-4-yl)phenyl)(octadecylamino)methyl]-
phosphonate 4j
Yield: 80%; Rf: 0.50; Eluent: ethyl acetate/hexane, 8:2 v/v;
1H NMR (300MHz, CDCl3) d (ppm): 0.77 (t, 3H, –CH3, J¼ 6.6Hz),
1.06–1.41 (m, 38H, –CH3, –CH2–), 2.39 (m, 2H, –CH2–NH–), 3.05
(br s, 1H, NH), 3.73 (m, 1H, –OCH2–), 3.84–4.01 (m, 4H, –OCH2–,
CHP), 4.53 (m, 1H, H50), 4.80–4.91 (m, 2H, H40, H50), 6.06 (m, 1H,
H30), 6.21 (m, 1H, H20), 6.47 (d, 1H, H10, J¼4.0Hz), 7.30–7.55 (m,
13H, Ar–H, CH–triazole), 7.88–8.00 (m, 7H, Ar–H). 13C NMR
(75MHz, CDCl3) d (ppm): 14.10, 16.33–16.47 (CH3), 22.67,
27.18, 29.34–29.82, 31.91, 48.60 (CH2), 59.50 (CHP), 63.01–
63.55 (C50, CH2), 71.64 (C20), 75.27 (C30), 81.28 (C40), 90.40 (C10),
118.40, 125.76, 128.53–129.89, 133.46–133.86 (phenyl–CH,
triazole–CH), 135.00 (phenyl–C), 149.00 (triazole–C), 165.05–
166.04 (CO). ESI-MS (MþH), m/z calcd. for C57H75N4O10P:
1007.20,found:1007.90;HRMS(MþK):calcd.forC57H75N4O10PK:
1045.48524, found: 1045.48309.
General procedure for the synthesis of diethyl [(4-(b-D-
ribofuranos-1-yl)-1,2,3-triazol-4-yl)(aryl or alkylamino)-
(phenyl)methyl]phosphonates 5a–j
To a solution of 1,2,3-triazole nucleoside analogs 4
(0.45mmol) in dry methanol (2.5mL), sodium methoxide
(1 equiv.) was added. The reaction mixture was stirred at
room temperature until the reaction was complete (30min).
The neutralization was performed with AmberliteIR120
hydrogen form. Afterwards the residue was filtered and
evaporated. The crude product was purified by flash silica gel
chromatography.
Diethyl [(4-(1-(b-D-ribofuranos-1-yl)-1,2,3-triazol-4-yl)-
phenyl)(phenylamino)methyl]phosphonate 5a
Yield: 98%; Rf: 0.30; Eluent: CH2Cl2/MeOH, 95:5 v/v;
1H NMR
(300MHz, CDCl3) d (ppm): 0.98–1.18 (m, 6H, –CH3), 3.61 (m, 1H,
H-50A), 3.69–3.86 (m, 4H, –OCH2–, H-50B, H-40), 3.93–4.02 (m,
4H, –OCH2–, H-20,30), 4.12 (d, 1H, –OH, J¼ 5.3Hz), 4.40 (t, 1H,
–OH, J¼ 5.0Hz), 4.54 (d, 1H, –OH, J¼5.3Hz), 4.68 (d, 1H, CHP,
J¼ 24.6Hz), 4.95 (br s, 1H, NH), 5.93 (d, 1H, H-10, J¼ 6.3Hz),
6.51–6.58 (m, 3H, Ar–H), 6.98 (t, 2H, Ar–H, J¼7.5Hz), 7.30
(m, 2H, Ar–H), 7.42 (d, 2H, Ar–H, J¼ 7.5Hz), 7.82 (s, 1H,
CH–triazole). 13C NMR (75MHz, CDCl3) d (ppm): 16.15–16.41
(CH3), 54.55 (CHP), 61.88–63.79 (C50, CH2), 70.87 (C20), 75.99
(C30), 85.84 (C40), 92.88 (C10), 113.95, 118.60, 120.00, 125.86,
128.36–129.52 (phenyl–CH, triazole–CH), 135.79, 146.11–
146.73 (phenyl–C, triazole–C). ESI-MS (MþH), m/z calcd. for
C24H31N4O7P: 518.50, found: 520.00; HRMS (MþK): calcd. for
C24H31N4O7PK: 557.15619, found: 557.15544.
Diethyl [(4-(1-(b-D-ribofuranos-1-yl)-1,2,3-triazol-4-yl)-
phenyl)(2-chlorophenylamino)methyl]phosphonate 5b
Yield: 99%; Rf: 0.32; Eluent: CH2Cl2/MeOH, 95:5 v/v;
1H NMR
(300MHz, CDCl3) d (ppm): 1.08–1.26 (m, 6H, –CH3), 3.57–3.61
(m, 1H, H-50A), 3.69–3.79 (m, 4H, –OCH2–, H-50B, H-40), 3.84–
4.07 (m, 4H, –OCH2–, H-20,30), 4.11 (d, 1H, –OH, J¼ 5.3Hz), 4.38
(t, 1H, –OH, J¼5.0Hz), 4.52 (d, 1H, –OH, J¼ 5.3Hz), 4.72 (d, 1H,
CHP, J¼ 24.6Hz), 5.24 (br s, 1H, NH), 6.01 (d, 1H, H-10,
J¼ 6.3Hz), 6.43 (d, 1H, Ar–H, J¼8.1Hz), 6.58 (d, 1H, Ar–H,
J¼ 6.3Hz), 6.93 (t, 1H, Ar–H, J¼ 7.2Hz), 7.20 (m, 1H, Ar–H),
7.47 (t, 2H, Ar–H, J¼6.6Hz), 7.51 (m, 2H, Ar–H), 7.98 (s, 1H,
CH–triazole). 13C NMR (75MHz, CDCl3) d (ppm): 16.01–16.41
(CH3), 54.50 (CHP), 61.85–63.94 (C50, CH2), 70.90 (C20), 76.03
(C30), 85.89 (C40), 92.95 (C10), 112.75, 117.63, 118.84, 120.01,
122.39, 125.97, 127.76–128.12, 129.26, 133.73 (phenyl–CH,
triazole–CH), 120.09 (C–Cl), 129.73, 135.17, 141.96 (phenyl–C),
146.68 (triazole–C). ESI-MS (MþH),m/z calcd. forC24H30ClN4O7P:
552.94, found: 553.80; HRMS (MþK): calcd. for C24H30ClN4O7PK:
591.11722, found: 591.11690.
Diethyl [(4-(1-(b-D-ribofuranos-1-yl)-1,2,3-triazol-4-yl)-
phenyl)(2-bromophenylamino)methyl]phosphonate 5c
Yield: 98%; Rf: 0.30; Eluent: CH2Cl2/MeOH, 95:5 v/v;
1H NMR
(300MHz, CDCl3) d (ppm): 1.10–1.20 (m, 6H, –CH3), 3.59–3.62
(m, 1H, H-50A), 3.71–3.88 (m, 4H, –OCH2–, H-50B, H-40), 3.90–
4.06 (m, 4H, –OCH2–, H-20,30), 4.11 (d, 1H, –OH, J¼ 5.3Hz), 4.39
(t, 1H, –OH, J¼5.0Hz), 4.51 (d, 1H, –OH, J¼ 5.3Hz), 4.76 (d, 1H,
CHP, J¼ 19.8Hz), 5.25 (br s, 1H, NH), 5.78 (d, 1H, H-10,
J¼ 6.3Hz), 6.34 (d, 1H, Ar–H, J¼ 7.2Hz), 6.43 (t, 1H, Ar–H,
J¼ 7.3Hz), 6.91 (t, 1H, Ar–H, J¼ 7.8Hz), 7.19 (m, 3H, Ar–H),
7.47 (m, 2H, Ar–H), 7.65 (s, 1H, CH–triazole). 13C NMR (75MHz,
CDCl3) d (ppm): 16.23–16.46 (CH3), 54.77 (CHP), 61.87–64.07
(C50, CH2), 70.90 (C20), 76.09 (C30), 85.95 (C40), 93.04 (C10),
110.55 (C–Br), 112.81, 119.36, 119.86, 125.99, 128.17–128.43,
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132.52 (phenyl–CH, triazole–CH), 129.74, 135.14, 145.95
(phenyl–C), 146.71 (triazole–C). ESI-MS (MþH), m/z calcd.
for C24H30BrN4O7P: 597.40, found: 598.00; HRMS (MþK): calcd.
for C24H30BrN4O7PK: 635.06671, found: 635.06660.
Diethyl [(4-(1-(b-D-ribofuranos-1-yl)-1,2,3-triazol-4-yl)-
phenyl)(4-bromophenylamino)methyl]phosphonate 5d
Yield: 99%; Rf: 0.33; Eluent: CH2Cl2/MeOH, 95:5 v/v;
1H NMR
(300MHz, CDCl3) d (ppm): 1.02–1.27 (m, 6H, –CH3), 3.65 (m, 1H,
H-50A), 3.68–3.79 (m, 4H, –OCH2–, H-50B, H-40), 3.84–4.14 (m,
4H, –OCH2–, H-20,30), 4.21 (d, 1H, –OH, J¼ 5.3Hz), 4.48 (t, 1H,
–OH, J¼ 5.0Hz), 4.66 (d, 1H, –OH, J¼5.3Hz), 4.74 (d, 1H, CHP,
J¼ 25.2Hz), 5.25 (br s, 1H, NH), 6.04 (d, 1H, H-10, J¼ 6.2Hz),
6.49 (d, 2H, Ar–H, J¼8.4Hz), 7.12 (d, 2H, Ar–H, J¼ 8.4Hz), 7.37
(d, 2H, Ar–H, J¼ 8.0Hz), 7.53 (d, 2H, Ar–H, J¼ 7.6Hz), 8.04 (s,
1H, CH–triazole). 13C NMR (75MHz, CDCl3) d (ppm): 16.15–
16.41 (CH3), 56.48 (CHP), 61.91–63.80 (C50, CH2), 70.86 (C20),
75.92 (C30), 85.75 (C40), 92.82 (C10), 110.14 (C–Br), 115.54,
120.14, 125.92, 128.38, 131.87 (phenyl–CH, triazole–CH),
129.63, 135.39, 145.47 (phenyl–C), 146.74 (triazole–C). ESI-
MS (MþH), m/z calcd. for C24H30BrN4O7P: 597.40, found:
598.10; HRMS (MþK): calcd. for C24H30BrN4O7PK: 635.06671,
found: 635.06616.
Diethyl [(4-(1-(b-D-ribofuranos-1-yl)-1,2,3-triazol-4-yl)-
phenyl)(4-fluorophenylamino)methyl]phosphonate 5e
Yield: 95%; Rf: 0.35; Eluent: CH2Cl2/MeOH, 95:5 v/v;
1H NMR
(300MHz, CDCl3) d (ppm): 0.78–1.18 (m, 6H, –CH3), 3.60 (m, 1H,
H-50A), 3.62–3.87 (m, 4H, –OCH2–, H-50B, H-40), 3.93–4.06 (m,
4H, –OCH2–, H-20,30), 4.11 (d, 1H, –OH, J¼ 5.3Hz), 4.39 (t, 1H,
–OH, J¼ 5.0Hz), 4.55 (d, 1H, –OH, J¼6.2Hz), 4.63 (d, 1H, CHP,
J¼ 24.6Hz), 5.29 (br s, 1H, NH), 5.95 (d, 1H, H-10, J¼ 6.4Hz),
6.46 (d, 2H, Ar–H, J¼8.0Hz), 6.66 (d, 2H, Ar–H, J¼ 8.1Hz), 7.28
(d, 2H, Ar–H, J¼ 7.6Hz), 7.44 (d, 2H, Ar–H, J¼ 7.5Hz), 7.93 (s,
1H, CH–triazole). 13C NMR (75MHz, CDCl3) d (ppm): 16.10–
16.37 (CH3), 55.14 (CHP), 61.88–63.75 (C50, CH2), 70.86 (C20),
75.96 (C30), 85.80 (C40), 92.86 (C10), 114.89–115.78, 120.07,
125.88, 128.39 (phenyl–CH, triazole–CH), 129.60, 135.65,
142.62 (phenyl–C), 146.75 (triazole–C), 154.67 (C–F). ESI-MS
(MþH), m/z calcd. for C24H30FN4O7P: 536.49, found: 538.10;
HRMS (MþK): calcd. for C24H30FN4O7PK: 575.14677, found:
575.14637.
Diethyl [(4-(1-(b-D-ribofuranos-1-yl)-1,2,3-triazol-4-yl)-
phenyl)(4-chloro-2-methylphenylamino)methyl]-
phosphonate 5f
Yield: 98%; Rf: 0.30; Eluent: CH2Cl2/MeOH, 95:5 v/v;
1H NMR
(300MHz, CDCl3) d (ppm): 0.83–1.02 (m, 6H, –CH3), 1.96 (s, 3H,
Ar–CH3), 3.49 (m, 1H, H-50A), 3.50–3.68 (m, 4H, –OCH2–, H-50B,
H-40), 3.71–4.84 (m, 4H, –OCH2–, H-20,30), 3.94 (d, 1H, –OH,
J¼ 5.0Hz), 4.12 (t, 1H, –OH, J¼7.0Hz), 4.21 (d, 1H, –OH,
J¼ 5.0Hz), 4.36 (br s, 1H, NH), 4.50 (d, 1H, CHP, J¼24.6Hz),
5.76 (d, 1H, H-10, J¼ 7.6Hz), 6.02 (d, 2H, Ar–H, J¼ 8.5Hz),
6.60 (d, 2H, Ar–H, J¼7.2Hz), 6.73 (s, 1H, Ar–H), 7.13 (d, 2H,
Ar–H, J¼6.6Hz), 7.32 (d, 2H, Ar–H, J¼6.3Hz), 7.77 (s, 1H,
CH–triazole). 13C NMR (75MHz, CDCl3) d (ppm): 16.29–16.53,
17.45 (CH3), 54.89 (CHP), 62.01–63.85 (C50, CH2), 70.97 (C20),
76.09 (C30), 85.93 (C40), 92.99 (C10), 112.58, 120.14, 126.07,
126.65, 128.19, 130.10 (phenyl–CH, triazole–CH), 123.00
(C–Cl), 125.01,129.81, 135.52, 142.91 (phenyl–C), 146.83
(triazole–C). ESI-MS (MþH), m/z calcd. for C25H32ClN4O7P:
566.97, found: 568.10; HRMS (MþK): calcd. for C25H32ClN4O7PK:
605.13287, found: 605.13238.
Diethyl [(4-(1-(b-D-ribofuranos-1-yl)-1,2,3-triazol-4-yl)-
phenyl)(2-naphthalenylamino)methyl]phosphonate 5g
Yield: 98%; Rf: 0.35; Eluent: CH2Cl2/MeOH, 95:5 v/v;
1H NMR
(300MHz, CDCl3) d (ppm): 0.99–1.38 (m, 6H, –CH3), 3.65 (m, 1H,
H-50A), 3.70–3.86 (m, 4H, –OCH2–, H-50B, H-40), 3.96–4.08 (m,
4H, –OCH2–, H-20,30), 4.18 (d, 1H, –OH, J¼ 5.4Hz), 4.46 (t, 1H,
–OH, J¼ 5.3Hz), 4.61 (d, 1H, –OH, J¼6.0Hz), 4.90 (d, 1H, CHP,
J¼ 24.0Hz), 5.35 (br s, 1H, NH), 5.99 (d, 1H, H-10, J¼ 6.6Hz),
6.72 (s, 1H, Ar–H), 7.01 (d, 1H, Ar–H, J¼ 8.1Hz), 7.10 (t, 1H,
Ar–H, J¼6.9Hz), 7.28 (dd, 1H, Ar–H, J¼ 7.2, 2.1Hz), 7.39–7.56
(m, 7H, Ar–H), 7.86 (s, 1H, CH–triazole). 13C NMR (75MHz,
CDCl3) d (ppm): 16.10–16.38 (CH3), 54.46 (CHP), 61.89, 63.54–
63.84 (C50, CH2), 70.84 (C20), 75.89 (C30), 85.74 (C40), 92.79 (C10),
106.27, 118.16, 120.05, 122.52, 125.83–126.39, 127.54, 128.31,
129.07 (phenyl–CH, triazole–CH), 127.86, 134.68, 135.56,
143.88, 144.06 (phenyl–C), 146.69 (triazole–C). ESI-MS
(MþH), m/z calcd. for C28H33N4O7P: 568.56, found: 570.20;
HRMS (MþK): calcd. for C28H33N4O7PK: 607.17184, found:
607.17152.
Diethyl [(4-(1-(b-D-ribofuranos-1-yl)-1,2,3-triazol-4-yl)-
phenyl)(benzylamino)methyl]phosphonate 5h
Yield: 95%; Rf: 0.30; Eluent: CH2Cl2/MeOH, 95:5 v/v;
1H NMR
(300MHz, CDCl3) d (ppm): 0.83–1.02 (m, 6H, –CH3), 2.57 (br s,
1H, NH), 3.27 (m, 2H, –CH2–NH–), 3.57 (m, 1H, H-50A), 3.60–3.71
(m, 4H, –OCH2–, H-50B, H-40), 3.73–3.83 (m, 4H, –OCH2–, H-
20,30), 3.98 (d, 1H, –OH, J¼ 5.0Hz), 4.24 (t, 1H, –OH, J¼ 4.9Hz),
4.38 (d, 1H, –OH, J¼ 6.2Hz), 4.76 (d, 1H, CHP, J¼ 24.6Hz), 5.83
(d, 1H, H-10, J¼6.3Hz), 6.98–7.03 (m, 5H, Ar–H), 7.16 (d, 2H,
Ar–H, J¼ 6.31Hz), 7.45 (d, 7H, Ar–H, J¼ 6.3Hz), 7.94 (s, 1H,
CH–triazole). 13C NMR (75MHz, CDCl3) d (ppm): 16.28–16.47
(CH3), 54.28 (CHP), 56.00, 62.50–63.50 (C50, CH2), 71.00 (C20),
76.26 (C30), 84.50 (C40), 93.22 (C10), 119.50, 126.03, 127.50,
128.58–130.06 (phenyl–CH, triazole–CH), 135.50, 139.00
(phenyl–C), 147.50 (triazole–C). ESI-MS (MþH), m/z calcd.
for C25H33N4O7P: 532.53, found: 534.10; HRMS (MþK): calcd.
for C25H33N4O7PK: 571.17184, found: 571.17077.
Diethyl [(4-(1-(b-D-ribofuranos-1-yl)-1,2,3-triazol-4-yl)-
phenyl)(dodecylamino)methyl]phosphonate 5i
Yield: 96%; Rf: 0.34; Eluant: CH2Cl2/MeOH, 95:5 v/v;
1H NMR
(300MHz, CDCl3) d (ppm): 0.92 (m, 6H, –OCH2CH3, –CH3), 1.15–
1.67 (m, 23H, –CH2–, –OCH2CH3), 7.60 (br s, 1H, NH), 2.33 (m,
2H, –CH2–NH–), 3.52 (m, 1H, H-50A), 3.83–3.91 (m, 4H, –OCH2–,
H-50B, H-40), 3.99–4.20 (m, 5H, –OCH2–, H-20,30, CHP), 4.31 (d,
1H, –OH, J¼ 5.0Hz), 4.63 (t, 1H, –OH, J¼ 4.9Hz), 4.91 (d, 1H,
–OH, J¼ 6.1Hz), 6.12 (d, 1H, H-10, J¼ 6.4Hz), 7.28 (d, 2H, Ar–H,
J¼ 8.2Hz), 7.85 (d, 2H, Ar–H, J¼8.2Hz), 8.07 (s, 1H,
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CH–triazole). 13C NMR (75MHz, CDCl3) d (ppm): 14.50, 16.00–
16.50 (CH3), 22.65, 27.05, 29.26–40.89 (CH2), 54.50 (CHP),
61.00–61.88 (C50, CH2), 70.85 (C20), 75.64 (C30), 86.48 (C40),
92.80 (C10), 121.10, 125.44, 128.41 (phenyl–CH, triazole–CH),
133.00–135.00 (phenyl–C), 147.0 (triazole–C). ESI-MS (MþH),
m/z calcd. for C30H51N4O7P: 610.72, found: 611.00.
Diethyl [(4-(1-(b-D-ribofuranos-1-yl)-1,2,3-triazol-4-yl)-
phenyl)(octadecylamino)methyl]phosphonate 5j
Yield: 97%; Rf: 0.36; Eluant: CH2Cl2/MeOH, 95:5 v/v;
1H NMR
(300MHz, CDCl3) d (ppm): 0.78 (t, 3H, –CH3, J¼6.9Hz), 1.04–
1.50 (m, 38H, –CH3, –CH2–), 1.99 (br s, 1H, NH), 2.21 (m, 2H,
–CH2–NH–), 3.70 (m, 1H, H-50A), 3.75–4.15 (m, 4H, –OCH2–, H-
50B, H-40), 4.20–4.46 (m, 5H, –OCH2–, H-20,30, CHP), 4.51 (d, 1H,
–OH, J¼5.0Hz), 4.87 (t, 1H, –OH, J¼ 5.2Hz), 5.29 (d, 1H, –OH,
J¼ 5.3Hz), 5.99 (d, 1H, H10, J¼4.0Hz), 7.34 (d, 2H, Ar–H,
J¼ 8.4Hz), 7.67 (d, 2H, Ar–H, J¼8.4Hz), 8.12 (s, 1H,
CH–triazole). 13C NMR (75MHz, CDCl3) d (ppm): 14.09,
16.00–16.26 (CH3), 22.67, 24.78, 27.08, 29.10–29.69, 31.91,
33.95 (CH2), 54.50 (CHP), 63.00–63.61 (C50, CH2), 71.50 (C20),
76.00 (C30), 86.00 (C40), 93.00 (C10), 121.00, 125.44, 128.41
(phenyl–CH, triazole–CH), 133.20–135.10 (phenyl–C), 147.25
(triazole–C). ESI-MS (MþH), m/z calcd. for C36H63N4O7P:
694.88, found: 696.10; HRMS (MþK): calcd. for C36H63N4O7PK:
733.40660, found: 733.40525.
Antiviral activity and cytotoxicity assays
The compounds were evaluated against the following viruses:
herpes simplex virus type 1 (HSV-1) strain KOS, thymidine
kinase-deficient (TK) HSV-1 KOS strain resistant to ACV
(ACVr), herpes simplex virus type 2 (HSV-2) strains Lyons andG,
varicella-zoster virus (VZV) strain Oka, TK VZV strain 071,
human cytomegalovirus (HCMV) strains AD-169 and Davis,
vaccinia virus Lederle strain, respiratory syncytial virus (RSV)
strain Long, vesicular stomatitis virus (VSV), Coxsackie B4,
parainfluenza 3, influenza virus A (subtypes H1N1, H3N2),
influenza virus B, Reovirus-1, Sindbis, Reovirus-1, Punta Toro,
human immunodeficiency virus type 1 strain IIIB, and human
immunodeficiency virus type 2 strain ROD. The antiviral, other
than anti-HIV, assays were based on inhibition of virus-
induced cytopathicity or plaque formation in human embry-
onic lung (HEL) fibroblasts, African greenmonkey cells (Vero),
human epithelial cells (HeLa), or Madin–Darby canine kidney
cells. Confluent cell cultures in microtiter 96-well plates were
inoculated with 100 CCID50 of virus (1 CCID50 being the virus
dose to infect 50% of the cell cultures) or with 20 plaque
forming units (PFU) (VZV) in the presence of varying
concentrations of the test compounds. Viral cytopathicity or
plaque formation was recorded as soon as it reached
completion in the control virus-infected cell cultures that
were not treated with the test compounds. Antiviral activity
was expressed as the EC50 or compound concentration
required to reduce virus-induced cytopathogenicity or viral
plaque formation by 50%. The methodology of the anti-HIV
assays was as follows: human CEM (3 105 cells/mL) were
infected with 100 CCID50 of HIV-1(IIIB) or HIV-2(ROD)/mL and
seeded in 200-mL-wells of a microtiter plate containing
appropriate dilutions of the test compounds. After 4 days
of incubation at 37°C, HIV-induced CEM giant cell formation
was examined microscopically.
Cytotoxicity of the test compounds was expressed as the
minimum cytotoxic concentration (MCC) or the compound
concentration that caused a microscopically detectable
alteration of cell morphology. Alternatively, the cytostatic
concentration was calculated as the CC50, or the compound
concentration required reducing cell proliferation by 50%
relative to the number of cells in the untreated controls.
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